Skip to main content
OpenTrials

Clinical trial condition

Mantle Cell Lymphoma

Explore clinical trials studying Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

252 public trials 59 recruiting studies
Refine in advanced search Browse all conditions

Mantle Cell Lymphoma trial results

Active, not recruiting

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

NCT02682641

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Hospital Clínic de Barcelona Barcelona, Spain
  • Hospital de la Santa Creu i Sant Pau Barcelona, Spain
  • Hospital Universitario Vall d'Hebron Barcelona, Spain
  • Institut Català d'Oncologia Barcelona, Spain
View all 15 locations
View Trial Details
Active, not recruiting

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

NCT06192888

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Dana Farber Cancer Institute (Data Collection and Specimen Analysis) Boston, Massachusetts, United States
  • Mayo Clinic (Data Collection Only) Rochester, Minnesota, United States
  • Washington University (Data Collection Only) St Louis, Missouri, United States
  • Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) Basking Ridge, New Jersey, United States
View Trial Details
Active, not recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Active, not recruiting

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT03842696

Conditions
Acute Leukemia in Remission, Blast Crisis, Bone Marrow Diseases, +37 more
Locations
  • University of Colorado Aurora, Colorado, United States
  • Emory University Atlanta, Georgia, United States
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
  • University of Michigan Health System Ann Arbor, Michigan, United States
View Trial Details
Active, not recruiting

Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

NCT04882475

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • ASST Grande Ospedale Metropolitano Niguarda Milan, MI, Italy
  • AOU Senese - U.O.C. Ematologia Siena, SI, Italy
  • Centro Riferimento Oncologico - S.O.C. Oncologia Medica A Aviano, Italy
  • ASST Spedali Civili di Brescia - Ematologia Brescia, Italy
View all 16 locations
View Trial Details
Active, not recruiting

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

NCT04072458

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +40 more
Locations
  • Georgia Cancer Center Augusta, Georgia, United States
  • New York Medical College / Westchester Medical Center Valhalla, New York, United States
  • Sarah Cannon Research Institute/Tennesee Oncology Nashville, Tennessee, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details
Active, not recruiting

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

NCT04624958

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Guangdong General Hospital Guangzhou, Guangdong, China
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • The First Affiliated Hospital of Guangdong Pharmaceutical University Guangzhou, Guangdong, China
View Trial Details

Related conditions